Study details
Enrolling now
Psilocybin or Ketamine for Alcohol Use Disorder
University of Iowa
NCT IDNCT06405607ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
80
Study length
about 2.9 years
Ages
21–65
Locations
1 site in IA
What this study is about
Researchers are testing whether psilocybin or ketamine can help people with alcohol use disorder. The trial will involve two groups: one group will receive psilocybin, and another group will receive ketamine, both along with therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ketamine
- 2.Take Psilocybin
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)
Drug routes
oral
Body systems
Psychiatry / Mental Health